Pateclizumab
Humanized (from mouse) | |
|---|---|
| Target | lymphotoxin alpha |
| Clinical data | |
| Other names | MLTA3698A |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6436H9910N1710O2004S44 |
| Molar mass | 144716.68 g·mol−1 |
  (what is this?) (verify) | |
Pateclizumab (MLTA3698A) is an immunomodulator. It binds to lymphotoxin alpha.[1][2][3][4][5][6]
This drug was developed by
Roche
.
References
- ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).[dead link]
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab, American Medical Association.
- PMID 25359150.
- PMID 22225620.
- S2CID 41454952.
- S2CID 3910200.